Author Archive for: TG

After more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or the United States has yet been shown to slow or modify disease progression. Against that backdrop, 4Moving Biotech (4MB) is betting that a familiar drug class, GLP-1 receptor agonists, can succeed where others have fallen short.

Aerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025.

Stockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab).

Novartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has therefore issued a cautious outlook for 2026. The CEO’s high, bonus-driven remuneration has sparked debate.

Pentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.